Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.560
-0.020 (-0.78%)
At close: Apr 10, 2026, 4:00 PM EDT
2.550
-0.010 (-0.39%)
After-hours: Apr 10, 2026, 7:53 PM EDT
BDTX Revenue
In the year 2025, Black Diamond Therapeutics had annual revenue of $70.00M.
Revenue (ttm)
$70.00M
Revenue Growth
n/a
P/S Ratio
2.10
Revenue / Employee
$3,333,333
Employees
21
Market Cap
146.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 114.20M |
| Spero Therapeutics | 66.80M |
| Fate Therapeutics | 6.65M |
| Humacyte | 2.04M |
| Oramed Pharmaceuticals | 2.00M |
BDTX News
- 25 days ago - Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data - Benzinga
- 4 months ago - Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM - GlobeNewsWire
- 4 months ago - Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - GlobeNewsWire
- 5 months ago - Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga
- 8 months ago - Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire